Don't Routinely Recommend Repatha (Evolocumab) for High Cholesterol
Repatha (rih-PATH-ah, evolocumab) is the first "PCSK9 inhibitor" approved for high cholesterol in Canada.
It works by preventing PCSK9...proprotein convertase subtilisin/kexin type 9...from binding and degrading liver LDL receptors. This leads to more LDL receptors...and more LDL cholesterol clearing from the blood.
Repatha can lower LDL about 60% in patients already receiving maximum statin doses.